As S1P1 modulators, such as ozanimod, are associated with a decrease of specific cytokines under inflammatory conditions,6, 23 we assessed the impact of ozanimod on key inflammatory mediators in patients with severe COVID‐19. This evidence concerns the gene S1PR1 and COVID-19.